Foley Hoag Advises Dana-Farber on Monetizing Royalty Interests Derived from Immunotherapy Patents with CPPIB

$100M+ transaction will provide essential funds to support critical cancer research

August 9, 2016

Foley Hoag LLP represented Dana-Farber Cancer Institute (DFCI) in monetizing a portion of its interest in royalties defined by certain licensing agreements related to its Programmed Death Ligand-1 (PD-L1) intellectual property. This $100M+ transaction was based on patents Foley Hoag acquired for DFCI and will provide essential funds to support critical cancer research.

PD-L1 inhibitors are immuno-oncology drugs used for the treatment of various types of metastatic cancer. CPPIB Credit Europe S.à r.l., a wholly owned subsidiary of Canada Pension Plan Investment Board, has paid $100 million upfront to acquire a portion of DFCI’s royalty interests and has committed to pay up to $68 million in additional payments, subject to certain conditions.

Foley Hoag attorneys DeAnn Smith and Philip Choi represented DFCI as IP counsel in this matter.

About Foley Hoag LLP

Foley Hoag provides innovative, strategic legal services to public, private and government clients across the globe. We have premier capabilities in the life sciences, healthcare, technology, energy, professional services and investment management fields, and in cross-border disputes. Our professionals  possess the skills  and experience to provide exceptional senior level service to clients ranging from startups to multinational companies to sovereign states. For more information, visit www.foleyhoag.com or follow @FoleyHoag on Twitter.